文献速递糖尿病

2型糖尿病中失眠(症状)患病率及其与代谢参数和血糖控制的关联:荟萃分析

Prevalence of Insomnia (Symptoms) in T2D and Association With Metabolic Parameters and Glycemic Control: Meta-Analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该系统综述与荟萃分析检索截至2018年3月的文献,纳入78项研究,评估2型糖尿病患者失眠(症状)的患病率及其与代谢参数和血糖控制的关联。汇总患病率为39%(95%CI 34-44),失眠(症状)与较高的HbA1c(平均差0.23% [0.1-0.4])和空腹血糖(平均差0.40 mmol/L [0.2-0.7])相关,证据等级低至极低。

要点

  • 2型糖尿病患者失眠(症状)的汇总患病率为39%(95%CI 34-44)。
  • 失眠(症状)与较高的HbA1c(平均差0.23% [0.1-0.4])和空腹血糖(平均差0.40 mmol/L [0.2-0.7])相关。
  • 证据等级低至极低,且研究间异质性高,结果解释需谨慎。

核心结论

  • 2型糖尿病患者中失眠(症状)的患病率为39%(95%CI 34-44),且可能与不良血糖控制相关。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed/Embase截至2018年3月,纳入78项在2型糖尿病成人中报告失眠(症状)患病率和/或与代谢参数或血糖控制关联的研究。

主要发现

  • 失眠(症状)的汇总患病率为39%(95%CI 34-44),I2统计量为100%(P < 0.00001),GRADE证据等级极低。
  • 在2型糖尿病患者中,失眠(症状)与较高的HbA1c水平相关(平均差0.23% [0.1-0.4]),GRADE证据等级低。
  • 在2型糖尿病患者中,失眠(症状)与较高的空腹血糖水平相关(平均差0.40 mmol/L [0.2-0.7]),GRADE证据等级低。

临床怎么用

  • 在2型糖尿病管理中,可考虑评估失眠(症状),因其患病率较高且可能与血糖控制不佳相关。

局限性

  • 纳入研究的方法学质量相对较低且异质性高,增加了结果解释的困难。
  • 敏感性分析未发现明确的异质性来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to determine the prevalence of insomnia and insomnia symptoms and its association with metabolic parameters and glycemic control in people with type 2 diabetes (T2D) in a systematic review and meta-analysis. DATA SOURCES: A systematic literature search was conducted in PubMed/Embase until March 2018. STUDY SELECTION: Included studies described prevalence of insomnia or insomnia symptoms and/or its association with metabolic parameters or glycemic control in adults with T2D. DATA EXTRACTION: Data extraction was performed independently by 2 reviewers, on a standardized, prepiloted form. An adaptation of Quality Assessment Tool for Quantitative Studies was used to assess the methodological quality of the included studies. DATA SYNTHESIS: When possible, results were meta-analyzed using random-effects analysis and rated using Grading of Recommendations Assessment, Development and Evaluation (GRADE). RESULTS: A total of 11 329 titles/abstracts were screened and 224 were read full text in duplicate, of which 78 studies were included. The pooled prevalence of insomnia (symptoms) in people with T2D was 39% (95% confidence interval, 34-44) with I2 statistic of 100% (P < 0.00001), with a very low GRADE of evidence. Sensitivity analyses identified no clear sources of heterogeneity. Meta-analyses showed that in people with T2D, insomnia (symptoms) were associated with higher hemoglobin A1c levels (mean difference, 0.23% [0.1-0.4]) and higher fasting glucose levels (mean difference, 0.40 mmol/L [0.2-0.7]), with a low GRADE of evidence. The relative low methodological quality and high heterogeneity of the studies included in this meta-analysis complicate the interpretation of our results. CONCLUSIONS: The prevalence of insomnia (symptoms) is 39% (95% confidence interval, 34-44) in the T2D population and may be associated with deleterious glycemic control.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Koopman ADM, Beulens JW, Dijkstra T, et al. Prevalence of Insomnia (Symptoms) in T2D and Association With Metabolic Parameters and Glycemic Control: Meta-Analysis. J Clin Endocrinol Metab. 2020. PMID: 31603475. doi:10.1210/clinem/dgz065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。